Bictegravir Combo Treatment Non-inferior to Boosted Protease Inhibitors in HIV?
October 5th 2017A fixed-dose combination of bictegravir and emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) was non-inferior to boosted protease inhibitor (bPI)-based regimens in virologically suppressed adults with HIV, according to a recently-published phase 3 study.
Read More